Arterial Occlusive Diseases
Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
Subtype terms (13)
More specific conditions that are subtypes of Arterial Occlusive Diseases in the MeSH hierarchy.
- Arteriosclerosis
32 drugs (25 approved, 7 experimental)
- Carotid Stenosis
59 drugs (42 approved, 17 experimental)
- Fibromuscular Dysplasia
- Leriche Syndrome
1 drug approved
- Malignant Atrophic Papulosis
2 drugs approved
- Median Arcuate Ligament Syndrome
- Mesenteric Vascular Occlusion
- Moyamoya Disease
7 drugs (5 approved, 2 experimental)
- Popliteal Artery Entrapment Syndrome
1 drug approved
- Renal Artery Obstruction
18 drugs (14 approved, 4 experimental)
- Retinal Artery Occlusion
9 drugs (7 approved, 2 experimental)
- Stenosis, Pulmonary Artery
- Thromboangiitis Obliterans
9 drugs (3 approved, 6 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (19)
Phase 3 trials (46)
- simvastatin
- vitamin d3
- nitroglycerin
- heparin
- methylprednisolone
- alfimeprase
- vitamin e
- beta carotene
- ketamine
- colestipol
- defibrotide
- prednisone
- edifoligide
- cannabidiol
- folic acid
- gadodiamide
- gadofosveset trisodium
- paclitaxel
- abciximab
- rivipansel
- warfarin
- hydroxyurea
- niacin
- vitamin c
- atorvastatin
- ticagrelor
- pravastatin
- semaglutide
- sufentanil
- alteplase
- +16 more
Phase 2 trials (23)
Phase 1 trials (9)
Organizations
Organization Involved with Phase 4 Indications (15)
- Bracco
- Guerbet
- Otsuka
- Medical Scientific Fund of the Mayor of Vienna
- Harbin Medical University
- Hoosier Cancer Research Network
- University of Vienna
- Karolinska Institute
- HOSPITAL UNIVERSITARIO DE CRUCES
- Aristotle University of Thessaloniki
- Basque Country University
- Aptiv Solutions
- University Clermont Auvergne
- Lepu Medical Technology (Beijing) Co., Ltd.
- Chinese Society of Cardiology
Organization Involved with Phase 3 Indications (31)
- Takeda
- Bristol-Myers Squibb
- Sanofi
- Arca Biopharma, Inc.
- Anesiva, Inc.
- Beijing Northland Biotech. Co., Ltd.
- Boston Scientific Corporation
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pittsburgh
- Harvard University
- University of Heidelberg
- University of Oslo
- University of Ottawa
- University of Southern California
- University of Bern
- Capital Medical University
- Universitaets-Herzzentrum
- University of Sao Paulo
- University of North Carolina at Chapel Hill
- University of Nantes
- Alfa Wassermann
- Franziskus Hospital, Berlin
- Technical University of Dresden
- University of Tuebingen
- Statistics and Epidemiology Research Corporation
- General Electric
- Medac
- Stiftungsklinikum Boppard
- Herzzentrum Bad Krotzingen
- University of Antwerp
- +1 more
Organization Involved with Phase 2 Indications (30)
- Merck
- Grifols
- Apceth GmbH & Co. KG
- Endovasc
- FGK Clinical Research GmbH
- NicOx
- Rheacell GmbH & Co. KG
- Academia Sinica, Taiwan
- Dartmouth University
- Health Decisions
- Katholieke Universiteit Leuven
- Naestved Hospital
- National Cheng Kung University
- RTI International
- Tufts University
- University of Kiel
- University of Southern Denmark
- University of Copenhagen
- Wilhelminenspital der Stadt Wien
- National Taiwan University
- University of Massachusetts
- University of Perugia
- Johannes Gutenburg University
- TICEBA GmbH
- Granzer Regulatory Consulting & Services
- Research Unit, Naestved, Region Zealand, Denmark.
- Inova Health System
- ViroMed
- Oxurion NV.
- AnGes, Inc.
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (4)